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Glycosylation greatly influences the safety and efficacy of many of the highest-selling recombinant 
therapeutic proteins (rTPs). In order to define optimal cell culture feeding strategies that control 
rTP glycosylation, it is necessary to know how nucleotide sugars (NSs) are consumed towards host 
cell and rTP glycosylation. Here, we present a theoretical framework that integrates the reported 
glycoproteome of CHO cells, the number of N-linked and O-GalNAc glycosylation sites on individual 
host cell proteins (HCPs), and the carbohydrate content of CHO glycosphingolipids to estimate the 
demand of NSs towards CHO cell glycosylation. We have identified the most abundant N-linked and 
O-GalNAc CHO glycoproteins, obtained the weighted frequency of N-linked and O-GalNAc glycosites 
across the CHO cell proteome, and have derived stoichiometric coefficients for NS consumption towards 
CHO cell glycosylation. By combining the obtained stoichiometric coefficients with previously reported 
data for specific growth and productivity of CHO cells, we observe that the demand of NSs towards 
glycosylation is significant and, thus, is required to better understand the burden of glycosylation on 
cellular metabolism. The estimated demand of NSs towards CHO cell glycosylation can be used to 
rationally design feeding strategies that ensure optimal and consistent rTP glycosylation.
Glycosylation is the most prevalent and impactful post-translational modification of recombinant therapeutic 
proteins (rTP)1,2. Twenty of the fifty highest selling pharmaceutical products in 2014 were glycoproteins and all 
twenty contain asparagine-linked (N-linked) complex carbohydrates (glycans), with two also containing serine/
threonine-linked mucin type (O-GalNAc) glycans3. The relative abundance and monosaccharide composition 
of therapeutic protein glycoforms has been widely reported to influence the bioactivity, bioavailability, and bio-
compatibility of these molecules1,2. Given the close relationship between glycoform distribution and rTP safety 
and efficacy, understanding the fundamental aspects of protein glycosylation is of critical importance for the 
biopharmaceutical industry1,2,4.
Nucleotide sugars (NSs) are the direct link between cellular metabolism and the glycosylation process4,5. NSs 
are synthesised in the cytoplasm from nutrients commonly found in cell culture medium (e.g. glucose, glutamine, 
asparagine, and glycine) and are subsequently transported into the Golgi apparatus, where they are consumed in 
the glycosylation reactions. Several reports have linked decreased availability of NSs with reduced complexity of 
secreted glycans6–8. In addition, direct precursors for NS biosynthesis, such as N-acetylglucosamine (GlcNAc), 
galactose, N-acetylmannosamine (ManNAc), mannose, uridine, and cytosine, have been fed to the culture to 
ensure that NSs are sufficiently available to achieve adequate recombinant product glycosylation (reviewed 
recently in ref. 9). However, addition of these NS precursors has commonly been associated with reduced cell 
growth10–13; therefore, optimal NS precursor feeding strategies that can modulate recombinant product glyco-
sylation while minimising the impact on cell growth are needed12,14. Alongside experimental work aimed at 
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identifying such optimal feeding strategies, recently developed mathematical models15–17 could become a power-
ful tool for these purposes in the near future.
Crucially, the glycosylation of recombinant product (rTP), host cell proteins (HCPs), and lipids occurs simul-
taneously. This is substantiated by the close correlation observed between cell surface and rTP glycans reported 
recently12. As a consequence, a fraction of fed NS precursors does not reach their intended target, and identifying 
the demand of NSs required for HCP glycosylation is therefore necessary to define optimal NS precursor feeding 
strategies.
To date, two estimates for the demand of NSs towards mammalian cell HCP glycosylation have been made16,17. 
Both were obtained by combining the frequency of N-linked and O-GalNAc glycosylation sites reported across 
the entire SwissProt database18 with the relative abundance of each monosaccharide present in the reported gly-
come of human activated B-cells16 or CHO cells17. Despite providing useful initial approximations, these esti-
mates have limitations given that they do not account for the relative abundance of each protein within the host 
organism’s proteome or the number of glycosylation sites on each protein. In addition, these estimates have not 
included the consumption of NSs towards glycolipid synthesis.
Here, we present a theoretical framework to estimate the demand of all nucleotide sugars consumed towards 
CHO HCP N-linked and O-GalNAc glycosylation, as well as for glycolipid synthesis. Our strategy integrates 
recent CHO proteomic19 and glycomic20,21 data to include (i) the relative abundance of all reported glycoproteins 
within the CHO proteome, (ii) the frequency of N-linked and O-GalNAc glycosylation sites across the proteome, 
and (iii) the monosaccharide composition of all N-linked and O-GalNAc HCP glycans. We also include the 
reported monosaccharide content of CHO lipids22, so that this sink for NSs is accounted for.
Our framework derives stoichiometric coefficients for the demand of all nucleotide sugars consumed for 
CHO HCP glycosylation and glycosphingolipid synthesis. The obtained stoichiometric coefficients are sub-
sequently used to estimate how NS demand is partitioned between HCP, lipid, and rTP glycosylation23 in 
industrially-relevant mAb-producing CHO cells24–26. Our results indicate that NS consumption rates towards 
cellular and rTP glycosylation are within the same order of magnitude, suggesting that considering both is imper-
ative to achieve a comprehensive description of NS metabolism.
The overall framework presented herein provides an approximation of NS demand towards CHO cellular gly-
cosylation, which can aid in developing NS precursor feeding strategies that ensure control of rTP glycosylation 
without compromising cell growth and product yield. In addition, use of the estimated stoichiometric coefficients 
in advanced mathematical models for NS metabolism and glycosylation should improve model fidelity and take 
us one step closer to model-based design and control of feeding strategies that ensure optimal and consistent rTP 
glycosylation. Finally, we report the most abundant host cell N-linked and O-GalNAc glycoproteins in CHO cells 
as well as their individual contribution towards overall NS consumption. Monitoring the glycosylation profiles of 
this reduced set of glycoproteins could be used to track and predict the effect of NS precursor feeding strategies 
in the future.
Materials and Methods
In order to obtain an improved estimate for the demand of NSs towards CHO cell glycosylation, we required 
an estimate of (i) the relative abundance of CHO HCPs, (ii) the weighted frequency of N-linked and O-GalNAc 
glycan sites per protein, (iii) the average glycoform distribution of each type, and (iv) NS demand for glycolipid 
synthesis. The workflow employed to obtain each of these components and the stoichiometric coefficients of NS 
consumption towards CHO HCP glycosylation are detailed in Fig. 1.
Step 1: CHO HCP relative quantification. The reported proteome of CHO cells19 was compared with the 
SwissProt database27 using BLAST28 to obtain the closest reviewed homolog for each HCP. The sequence, length 
(Leni), and molecular weight (MWi) for each homolog were also retrieved from SwissProt. The obtained amino 
acid lengths and reported spectral counts19 (SCi) were then used to calculate the relative abundance (Zi) of each 
CHO HCP using Eqs 1 and 2, as described previously29,30. With the obtained values for Zi, the weighted average 
amino acid length (LenHCP ) and molecular weight (MWHCP ) of CHO HCPs were calculated using Eqs 3 and 4. 
The list for all reported HCPs, the obtained homologs, and the calculations for Zi, LenHCP , and MWHCP  are pre-
sented in Supplementary Table ST1. The weighted relative abundance of the amino acids present in CHO HCPs 
x( )Aacj  was obtained with Eq. 5, using the amino acid frequency in the sequence of each homologous protein 
(nAacj) and Zi. The calculation of xAacj across the whole CHO proteome is presented in Supplementary Table ST2.
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Figure 1. Workflow for the estimation of stoichiometric coefficients for nucleotide sugar demand towards 
CHO cell and mAb glycosylation. Step 1: the CHO proteome19 was BLASTed28 against the SwissProt database27 
to obtain the corresponding confirmed homologous proteins. The length, amino acid sequence, molecular 
weight, and potential N-linked glycosylation sites for each homologous protein were extracted from the 
database. Using the protein length and the spectral counts available from literature19, the relative abundance of 
each homologous protein (Zi) was obtained29,30 (Eq. 2). With Zi, the weighted average protein length Len( )HCP , 
molecular weight MW( )HCP , and amino acid content were calculated (Eqs 3–5). Step 2: the amino acid sequences 
of potentially N-glycosylated homologous proteins were analysed with the NetNGlyc 1.0 server32 to obtain the 
number of occupied N-linked sites per HCP S( )Nglyc i
HCP
, . The weighted average number of N-linked glycosites across 
the CHO proteome S( )Nglyc
HCP  was obtained by combining SNglyc i
HCP
,  with Zi (Eq. 6). Step 3: the CHO O-GalNAc 
glycoproteome21 was BLASTed28 against the SwissProt database27. The obtained list of homologous proteins was 
aligned with the one from the CHO proteome to obtain the weighted average number of O-GalNAc glycosites 
across the CHO proteome S( )Oglyc
HCP  (Eq. 7). Step 4: the weighted average monosaccharide composition of CHO 
HCP N-linked f( )N S
NglycHCP
k
 and O-GalNAc glycans f( )N S
OglycHCP
k
 was obtained from the CHO glycome20 (Fig. 2) 
using Eqs 8 and 9. The average N-linked glycan monosaccharide composition for a commercial mAb f( )N S
Nglyc mAb,
k
 
was also obtained from literature23 (Fig. 2). The demand of NSs towards glycolipid synthesis was obtained from 
the reported monosaccharide content of CHO cell glycosphingolipids relative to total protein content F( )N S
GL
k
22. 
Step 5: the stoichiometric coefficients for the demand of NSs towards HCP N-linked ν( )N S
NglycHCP
k
, O-GalNAc 
ν( )N S
OglycHCP
k
, lipid ν( )N S
GL
k
, and mAb N-linked ν( )N S
mAb Nglyc,
k
 glycosylation were calculated using the corresponding 
equations included at the bottom of the figure using a dry cell weight (Mcell) of 271pg/cell34, a protein content 
(Zprot) of 74.2% (w/w)35, and a mAb molecular weight (MWmAb) of 148,545 g/mol. All data and calculations are 
presented in Supplementary Tables ST1–ST10.
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Step 2: N-linked glycan sites per protein. The vast majority (> 90%) of all reported N-linked glycosites 
in SwissProt have not been experimentally confirmed to be occupied31. In order to further refine the estimate by 
considering macroheterogeneity (variations in N-glycan occupancy of each potential site), the amino acid 
sequences for all potential N-linked glycoproteins were analysed using the NetNGlyc 1.0 server (http://www.cbs.
dtu.dk/services/NetNGlyc/)32. To obtain a conservative estimate for N-linked glycosites, only ones found to be 
within the upper thresholds (+ + and + + + ) were considered to be occupied. The obtained number of occupied 
N-linked glycosites (SNglyc i
HCP
, ) was multiplied by the respective protein’s relative abundance (Zi) and then summed 
to obtain the weighted number of N-linked glycosites across the entire CHO proteome (SNglyc
HCP ), as shown in Eq. 6. 
All calculations performed to estimate SNglyc
HCP , along with the contribution of each predicted N-glycoprotein to the weighted 
number of N-glycosites, are presented in Supplementary Table ST3.
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Step 3: O-linked glycan sites per protein. As of February 2016, 2,375 O-GalNAc glycosylation sites were 
reported in a total of 182,101 eukaryotic glycoproteins in the SwissProt database27. However, a recent study by 
Yang and collaborators21 found 1,548 O-GalNAc glycosites in the proteome of CHO cells alone, suggesting that 
O-GalNAc glycosylation may be underreported in SwissProt. The low frequency of reported O-GalNAc sites 
is possibly due to the challenging analytical methods required for mapping, identifying, and quantifying these 
glycan types which lack a consensus amino acid sequon, may have core structure variability, and cluster densely 
in Ser/Pro/Thr-rich domains33.
In order to obtain the frequency of these post-translational modifications, the reported O-GalNAc glycopro-
teome of CHO cells was used21. The work of Yang et al. relied on engineering CHO cells to produce truncated 
O-GalNAc glycans that simplified glycopeptide enrichment using lectin chromatography and streamlined data 
analysis and interpretation for mapping all O-GalNAc glycosylation sites. The glycoproteome from this study was 
BLASTed28 against the SwissProt27 database to obtain a set of confirmed homologous O-GalNAc glycoproteins. 
This set was then aligned with the closest homologous proteins obtained for the entire CHO proteome. Once 
aligned, the number of O-GalNAc glycosites per HCP (SNglyc i
HCP
, ) reported by Yang et al.21 was multiplied by the 
relative abundance of each HCP (Zi) and summed (Eq. 7) to obtain the weighted average number of O-GalNAc 
glycosites across the CHO proteome (SOglyc
HCP). All calculations and the contribution of individual proteins to SOglyc
HCP 
are presented in Supplementary Table ST4.
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Step 4. Weighted average monosaccharide composition of CHO HCP and mAb glycans. In 
order to obtain the weighted average monosaccharide composition of CHO HCP glycans ( fN S
NglycHCP
k
and fN S
OglycHCP
k
), 
the reported20 relative abundance of each N-linked glycan species l and O-GalNAc glycan species m (xNglyc l
HCP
,  and 
xOglyc m
HCP
, , respectively) presented in Fig. 2 was multiplied by the frequency with which the monosaccharide species 
appears in each glycan (nN S l m, /k ), as shown in Eqs 8 and 9. Each monosaccharide present on the reported HCP glycans was assumed to be sourced from the respective nucleotide sugar (NS). All N-linked HCP glycans were 
assumed to contain three glucose (sourced from uridine diphosphate glucose – UDP-Glc) and nine mannose 
(sourced from guanosine diphosphate mannose – GDP-Man) residues, given that all N-linked glycans are synthe-
sised from the Glc3Man9GlcNAc2 precursor oligosaccharide depicted on the top left corner of Fig. 2. These calcu-
lations are detailed in Supplementary Tables ST5 and ST6.
The weighted average monosaccharide composition of mAb glycans ( fN S
Nglyc mAb,
k
) was obtained by combining 
the relative abundance of mAb constant fragment (Fc) N-glycans (xNglyc q
mAb
, ) reported for trastuzumab23 (Fig. 2) 
with the frequency of each monosaccharide residue in these Fc carbohydrates (nN S q,k ), as shown in Eq. 10. The Fc 
glycoform distribution of trastuzumab23 was used because product glycan data is not reported in the work cited 
herein for the estimation of NS consumption between host cell and product glycosylation24–26. Furthermore, data 
for trastuzumab glycosylation was selected for the calculation of fN S
Nglyc mAb,
k
 given that this product contains gly-
cans that are representative of almost all commercially-available mAbs (complex biantennary with varying 
degrees of fucosylation and galactosylation1,2,4) and can be considered a ‘model’ CHO-derived product due to its 
isotype (IgG1 – the most common among therapeutic mAbs4) and the fact that it has been manufactured using 
CHO cells for nearly two decades3. Similarly to HCP glycans, all mAb Fc N-linked glycans were assumed to 
require three glucose and nine mannose residues for their formation. All calculations performed to obtain 
fN S
Nglyc mAb,
k
 are presented in Supplementary Table ST7.
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The monosaccharide content of total CHO cell lipids relative to total protein content (FN S
GL
k
) was obtained from 
the work by Briles and collaborators22. With these values, the distribution of CHO cell glycosphingolipids (Fig. 2) 
was calculated as shown in Supplementary Table ST8.
Step 5: Stoichiometric coefficients of NSs per cell. The final step was to calculate the stoichiometric 
coefficients for the demand of NSs towards CHO HCP N-linked and O-GalNAc glycan synthesis (νN S
NglycHCP
k
 and 
νN S
OglycHCP
k
, respectively), CHO cell glycolipid synthesis (νN S
GL
k
), and mAb N-linked glycosylation (νN S
Nglyc mAb,
k
). 
νN S
NglycHCP
k
, νN S
OglycHCP
k
, and νN S
GL
k
 represent the weighted average number of nanomoles of NSs consumed towards 
each type of glycosylation per million cells. The stoichiometric coefficient of NS demand towards HCP N-linked 
glycosylation was obtained by combining the dry weight of CHO cells (Mcell), the protein content of CHO cells 
(Zprot in %w/w), the weighted average molecular weight of CHO HCPs (MWHCP ), the weighted average number 
of N-linked glycosites across the CHO proteome (SNglyc i
HCP
, ), and the weighted average monosaccharide composition 
of CHO HCP glycans ( fN S
NglycHCP
k
), as shown in Eq. 11. The stoichiometric coefficient for NS demand towards CHO 
HCP O-GalNAc glycosylation was calculated in a similar fashion, as presented in Eq. 12. For these calculations, 
the dry weight of CHO cells reported by Carinhas et al.34 (Mcell = 271 pg/cell) and a cellular protein content of 
Zprot = 74.2%35 were used. The value for dry cell weight was selected because it is representative of those that have 
previously been reported for CHO cells36,37, and Zprot = 74.2% was selected given that similar values have been 
Figure 2. Glycan distributions produced by CHO cells. The distribution of N-linked and O-GalNAc glycans 
found on CHO HCPs is presented within the blue dashed box20. The O-GalNAc glycans are highlighted within 
the solid shaded box. The distribution of lipid-bound glycans is shown in the belted grey box22. The average 
composition of mAb Fc-bound N-linked glycans present on a commercial mAb (trastuzumab) produced by 
CHO cells23 is shown inside the orange dashed box.
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reported for several mammalian cell types, including CHO34–38. Although different assays have been used to 
quantify Zprot (e.g. Bradford34 and Biuret38), the values that are reported typically range between 70% and 80%. The 
stoichiometric coefficient for NS consumption towards lipid glycosylation (νN S
GL
k
) was obtained by multiplying the 
monosaccharide content of CHO cell lipids relative to total protein content (FN S
GL
k
)22 by the above mentioned val-
ues for Mcell and Zprot, as shown in Eq. 13. The calculations to obtain νN S
NglycHCP
k
, νN S
OglycHCP
k
, and νN S
GL
k
 are shown in 
Supplementary Table ST9.
The stoichiometric coefficients for NS demand towards mAb Fc N-linked glycosylation ν( )N S
Nglyc mAb,
k
 were cal-
culated with Eq. 14 using the values of fN S
Nglyc mAb,
k
 that were obtained as described in Step 4. The mAb was assumed 
to contain two N-linked glycosites on its Fc =S( 2)Nglyc
mAb . The molecular weight of the mAb was calculated using 
the amino acid sequence of trastuzumab and its weighted average glycan composition23 to yield a value of 
MWmAb = 148,545 g/mol. The calculation of νN S
Nglyc mAb,
k
 is presented in Supplementary Table ST9.
ν =






M Z
MW
S f
(11)
NS
NglycHCP cell prot
HCP
Nglyc
HCP
NS
NglycHCP
k k
ν =






M Z
MW
S f
(12)
NS
OglycHCP cell prot
HCP
Oglyc
HCP
NS
OglycHCP
k k
ν = M Z F (13)NS
GL
cell prot NS
GL
k k
ν =





MW
S f1
(14)
NS
Nglyc mAb
mAb
Nglyc
mAb
NS
Nglyc mAb, ,
k k
Other types of cellular glycosylation. Although other types of glycosylation exist in mammalian cells, 
they have not been considered to greatly impact cellular NS demand due to their low abundance relative to 
the amount of HCP N-linked and O-GalNAc glycans and glycosphingolipids39,40. For example, O-mannose and 
O-fucose linked glycans have been indeed observed in the CHO cell glycoproteome, but at nearly undetectable 
levels20.
Similarly, dolichol pyrophosphate-linked oligosaccharides (Dol-PP-OS) have also been reported to be present 
in CHO cells41, but it is likely that NS demand towards this glycolipid pool is small compared to that of HCP and 
glycosphingolipid glycosylation. Intracellular accumulation of Dol-PP-OSs has been reported to depend on the 
availability of dolichol phosphate (Dol-P)42, which in turn, has been identified as a small fraction (only a few per-
cent) of total cellular lipids in rat and mouse tissues43. In addition, the majority of monosaccharide constituents 
of the Dol-PP-OS precursor are cleaved off during glycan processing within the Golgi apparatus and are likely 
recycled for de novo synthesis of Dol-PP-OS. Therefore, it is possible to assume that NS consumption towards 
Dol-PP-OS synthesis is low compared to glycosphingolipid and HCP glycosylation and is, thus, negligible within 
our proposed framework.
Proteoglycans. Proteoglycans, which contain linear carbohydrate chains constituted by tandem disaccha-
ride motifs (glycosaminoglycans), are more commonly associated with cell adhesion in connective tissue44, and 
thus, may not be prevalent in CHO cells39. In order to evaluate whether this potential source of NS consumption 
is low compared to cellular N-linked, O-GalNAc, and glycosphingolipid glycosylation, the frequency of this gly-
cosylation type was estimated based on the CHO proteome quantification described in Step 1 above.
Specifically, the database of closest confirmed homologs to the CHO proteome (ST1) was queried for presence 
of the forty-three known proteoglycans44. The weighted average frequency of glycosaminoglycan (GAG) sites per 
CHO HCP (SGAG
HCP) was obtained by multiplying the reported number of glycosaminoglycan (GAG) sites per pro-
teoglycan S( )GAG i
HCP
,  by the relative abundance of the corresponding protein (Zi) and summing this product across 
the entire CHO proteome, as shown in Eq. 15. These calculations are shown in Supplementary Table ST10.
∑=
=
S S Z
(15)GAG
HCP
i
NP
GAG i
HCP
i
1
,
Glycosylphosphatidylinositol (GPI) anchors. The glycophosphatidylinositol (GPI) anchor, which 
attaches proteins to the membrane of cells, also contains a carbohydrate component. The amount of free GPI and 
GPI-anchored proteins has also been reported to be low compared to N-linked, O-GalNAc, and glycosphingo-
lipid glycosylation39,40. In order to estimate the abundance of GPI glycans in CHO cells, the number of potential 
GPI-anchored CHO HCPs (SGPI i
HCP
, ) was obtained by submitting the amino acid sequences of all confirmed homol-
ogous CHO HCPs (ST1) to the PredGPI GPI-anchor prediction server (http://gpcr.biocomp.unibo.it/predgpi/
pred.htm)45. The obtained SGPI i
HCP
,  values were then multiplied by the relative abundance of each corresponding 
HCP (Zi) and summed (Eq. 16) to obtain the weighted average frequency of GPI-anchored HCPs (SGPI
HCP) across 
the CHO proteome. These calculations are detailed in Supplementary Table ST10. The number of free GPI sites 
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within CHO cells (SGPI
free) was obtained by multiplying SGPI
HCP by the ratio of free to occupied GPI sites (3.7oGPI/fGPI) 
reported for CHO cells39, as shown in Eq. 17. These calculations are also presented in Supplementary Table ST10.
∑=
=
S S Z
(16)GPI
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i
NP
GPI i
HCP
i
1
,
= .S S3 7 (17)GPI
free
GPI
HCP
Demand of NSs towards cellular and mAb glycosylation. Considering that the demand for NSs is 
partitioned between HCP, lipid, and mAb glycosylation, two limits can be identified: (i) when cell growth greatly 
exceeds mAb productivity and (ii) when mAb productivity considerably outweighs growth. Both scenarios could 
be observed in typical fed-batch culture, where during exponential growth phase, the demand of NSs towards 
cellular glycosylation would predominate, whereas during stationary phase, the demand of NSs towards cellular 
glycosylation would decrease considerably and demand towards mAb glycosylation would become significant. In 
order to cover both possibilities, data for the specific growth rate (μg) and specific mAb productivity (qp) corre-
sponding to a breadth of productivity to growth ratios µ=µR q( / )q p g/p g  reported for industrially-relevant CHO 
cells have been retrieved from recent publications24–26.
Specifically, two sets of values for μg and qp were extracted from each reference, the first corresponding to a low 
productivity to growth rate ratio (Dool-L24, Chus-L25, and Kant-L26), and the second corresponding to a high 
productivity to growth ratio (Dool-H24, Chus-H25, and Kant-H26) (Table 1). All but the μg and qp values obtained 
from Kant-H correspond to industrial CHO cell lines continuously expressing a recombinant mAb while growing 
exponentially. The selected μg and qp values are considered typical for industrial CHO bioprocesses (μg between 
0.03 h−1 and 0.05 h−1 and qp between 20 pg/cell/day to 70 pg/cell/day)46,47. The values for Kant-H correspond to 
engineered CHO cells undergoing stationary growth while being cultured under mild hypothermic conditions 
and in the presence of sodium butyrate. The Kant-H values were selected to have an extremely high µRq /p g that 
would be representative of the limit for scenario (ii) described above (qp = 94.05 pg/cell/day and μg = 0.011h−1). 
We must note that a qp value of 100 pg/cell/day is commonly viewed as the upper threshold for CHO cell mAb specific 
productivity48. In all references, qp was determined based on extracellular measurements of mAb titre. Chusainow 
et al. and Kantardjieff et al. determined mAb titre using ELISA, while Doolan et al. used protein A HPLC for mAb 
quantification.
In order to obtain estimates for NS demand towards HCP (DN S
NglycHCP
k
 and DN S
OglycHCP
k
), lipid (DN S
GL
k
), and mAb 
(DN S
Nglyc mAb,
k
) glycosylation under different growth and mAb productivity conditions, the μg and qp values were simply 
multiplied by the stoichiometric coefficients calculated in Step 5, as shown in Eqs 18–21. These calculations are detailed 
in Supplementary Table ST11.
ν µ=D (18)N S
NglycHCP
N S
NglycHCP
gk k
ν µ=D (19)N S
OglycHCP
N S
OglycHCP
gk k
ν µ=D (20)N S
GL
N S
GL
gk k
Productivity to growth ratios ( µRq p g/ )
Low High
Doolan et al.24 Chusainow et al.25 Kantardjieff et al.26 Doolan et al.24 Chusainow et al.25 Kantardjieff et al.26
μg (h−1) 0.031 0.03 0.025 0.011 0.011 0.011
qp ( )pgcell day 23.1 39.95 46.52 23.7 52.07 94.05
µRqp g/  






pg produced
cellproduced
31.1 56.2 78.2 89.8 192 359.5
Protein synthesis rates
Low High
HCP ( )pg protcell h 6.23 5.95 4.99 2.21 2.27 2.19
mAb ( )pg protcell h 0.96 1.66 1.94 0.99 2.17 3.92
Total ( )pg protcell h 7.20 7.62 6.93 3.20 4.44 6.11
% to mAb 13.4% 21.9% 28.0% 30.9% 48.8% 64.1%
Table 1.  mAb productivity to growth rate ratios and total protein synthesis rates.
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ν=D q (21)N S
Nglyc mAb
N S
Nglyc mAb
p
, ,
k k
By combining the assumed values for Mcell = 271pg/cell 34 and Zprot = 74.2%35 with the μg values obtained from 
literature24–26, cellular protein productivity can be estimated (Eq. 22). The obtained HCP, mAb, and total protein 
synthesis rates are shown in Table 1 and the corresponding calculations are presented in Supplementary Table 
ST11.
µ=q M Z (22)prot
HCP
cell prot g
Cellular glycosylation calculator. Although literature-derived experimental data has been used to 
perform all calculations reported herein, we must highlight that the supplementary file is a set of integrated 
spreadsheets that is amenable to analysis and modification by users to include experimental data for specific 
rTGP-producing CHO cell cultures. Users may readily adjust the relative abundance of HCP N-linked and 
O-GalNAc glycans (ST5 and ST6), the glycoform distribution of the recombinant product (ST7), the molecular 
weight and number of N-linked glycosites on the product (ST9), and the specific growth rate and productivity 
(ST11) to obtain stoichiometric coefficients for NS consumption towards recombinant product and cellular gly-
cosylation for any system. These coefficients can, in turn, be used to estimate the partition of NS consumption 
towards cellular and rTGP glycosylation for user-defined CHO cell culture data and can also be used as inputs for 
models of CHO cell metabolism.
Results and Discussion
Relative abundance of CHO cell proteins. The most highly abundant individual proteins are those 
associated with the cytoskeleton (e.g. γ -actin, β -actin, β -tubulin, α -tubulin, vimentin), glycolysis (glyceralde-
hyde-3-phosphate dehydrogenase, fructose-bisphosphate aldolase A), chromatin (e.g. histones H4 and H2B), 
ribosomes (e.g. 40S ribosomal protein S12 and S3A), and those involved in protein transcription, translation, and 
folding (e.g. heat shock cognate 71 kDa protein, eukaryotic translation initiation factor 5A-1, elongation factor 
1α -1, and peptidyl-prolyl cis-trans isomerase A). A full list of the CHO cell proteome including the relative abun-
dance of each protein is presented in Supplementary Table ST1.
Figure 3A compares the most abundant categories (as obtained through relative quantification and gene ontol-
ogy analysis) of CHO HCPs with those obtained from protein relative abundance data of a murine ovary cell line 
(http://pax-db.org/)49,50. Both datasets are in relative agreement for cytoskeletal, chromatin, and glycolysis and 
respiration proteins. Large deviations can be observed for HCPs involved in protein transcription, translation, 
and folding. Specifically, HCPs involved in protein biosynthesis (transcriptional, translational, and ribosomal 
proteins) are in considerably higher abundance in CHO cells than in the murine ovary cell line. These differences 
are likely to be species-specific and are consistent with the phenotypic traits (rapid proliferation and high protein 
productivity) that characterise CHO cells.
In order to further validate the proteome-based quantification, the relative abundance of amino acids in 
the CHO HCPs was compared with previously reported data on murine38 and CHO51 HCP amino acid content 
(Fig. 3B). In general, the trends in amino acid content are similar across all datasets. When compared with the 
murine hybridoma data, the proteome-derived amino acid distribution diverges only slightly, with the highest 
Figure 3. Relative abundance and amino acid composition of CHO host cell proteins. The relative 
abundance of the major categories for CHO HCPs are compared with those obtained from murine ovary 
cells49,50 (A). The amino acid composition of murine38 and CHO51 host cell proteins used in previous studies is 
compared with the one estimated from the CHO proteome (B).
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observed deviations being for glutamate (+ 2.0%), proline (− 1.7%), and lysine (+ 1.6%). These differences could 
be attributed to species-specific variations. When compared to the CHO dataset, the proteome-derived amino 
acid frequency diverges more. Particular differences can be seen for glutamate (− 4.1%), aspartate (− 2.9%), and 
lysine (− 1.5%). As the major deviations with respect to the CHO dataset are observed for amino acids that are 
products of deamination, this result could be an artefact of the analytical method. Another possibility is that the 
analytical method used by Selvarasu et al.51 quantified total amino acid concentration (free amino acids plus those 
contained in protein). Because glutamate and aspartate are the key amino acids involved in the aspartate-malate 
shuttle, and CHO cells have high activity of this process52, a considerable amount of free glutamate and aspartate 
would be expected in this cell type. However, we cannot rule out that the deviation is due to the spectral counting 
quantification method employed.
Frequency of N-linked and O-GalNAc glycosylation sites in CHO. The obtained frequencies for 
N-linked and O-GalNAc glycosylation sites in CHO HCPs are presented in Table 2. The frequency of O-GalNAc 
glycosylation is estimated to be 26.64 sites per 100 host cell proteins, while the frequency of N-linked glycosyla-
tion is lower, at 8.09 sites per 100 host cell proteins. These values are significantly lower than those derived in 
previous studies16,17, where N-glycosylation frequency was considered to be 170 sites per 100 host cell proteins 
and 158 O-GalNAc sites per 100 host cell proteins. These studies did not consider HCP relative abundance or the 
number of glycosylation sites per HCP. Precisely to refine these initial estimates, both of these components are 
included in our strategy to obtain more representative values of HCP N-linked and O-GalNAc glycosylation sites 
across the CHO proteome. When considering relative HCP abundance, only ~4% (mol/mol) of CHO HCPs con-
tain N-glycosites and ~6.5% (mol/mol) contain O-GalNAc sites. Furthermore, a recent publication estimates the 
frequency of N-linked glycosylation sites across the Pichia pastoris proteome at 1 site for every 4,691 amino acid 
residues53. Using our estimated value for weighted average CHO HCP length ( = .Len aac HCP413 6 /HCP ) and 
N-glycosite frequency ( = .S Sites HCP0 0809 /Nglyc
HCP ) a value of 1 N-glycosite for every 5,102 amino acid residues is 
obtained (a deviation of only 8%). Although differences between P. pastoris and mammalian cell lines are 
expected, it would seem unusual for them to span two orders of magnitude. Irani et al.53 obtained their N-glycosite 
frequency value by dividing the previously reported number of N-linked glycosites in P. pastoris by the total num-
ber of amino acid residues in that organism’s proteome. Our strategy for obtaining O-GalNAc glycosylation site 
frequency is analogous, given that data for the O-GalNAc glycosylation sites of CHO cells was available21. Overall, 
we believe that the estimates presented herein and those reported by Irani et al.53 are more accurate than the pre-
vious ones because HCP relative abundance and glycosylation site frequency have been considered. The relative 
abundance of all N-linked and O-GalNAc glycoproteins, along with their weighted contribution to glycosylation 
site frequency are presented in Supplementary Tables ST3 and ST4, respectively.
An interesting feature of our estimates is that the ten highest contributors (out of a total of 437 predicted 
N-linked glycoproteins) account for 50% of the overall N-linked glycosite frequency. Similarly, the ten highest 
contributors to O-GalNAc site frequency (out of 346 predicted O-GalNAc glycoproteins) account for 43% of 
the total O-GalNAc glycosite frequency (Fig. 4). The fact that a small subset of proteins contributes so heavily 
to CHO HCP glycosylation could prove extremely useful for monitoring HCP glycosylation experimentally. If 
dynamic variations in abundance, site occupancy, and glycoform distribution of these top ten contributors is 
representative of the remaining host cell glycoproteins, they could be used as markers for dynamic variations in 
HCP glycosylation.
Nine of the eighteen most abundant glycoproteins in the CHO proteome are involved in protein folding (Fig. 4). 
Five of these are chaperones (endoplasmin, hypoxia up-regulated protein 1, clusterin, 78 kDa glucose-regulated 
protein, and serpin H1), while four are either disulphide isomerases (protein disulphide-isomerase A3 and pro-
tein disulphide isomerase) or peptide isomerases (peptidyl-prolyl cis-trans isomerase A, peptidyl-prolyl cis-trans 
isomerase FKB10). It would be interesting to evaluate if the carbohydrates bound to these proteins influence their 
activity. If so, we could envision a situation where HCP glycosylation is limited by NS availability, which, in turn, 
would lead to accumulation of unfolded or misfolded proteins in the endoplasmic reticulum. Furthermore, many 
HCP Glycan frequency ( )sites100 HCPs
N-linked O-GalNAc
8.09 26.64
Nucleotide sugar stoichiometric coefficients
N-linked HCP 
( )nmolicells106
O-GalNAc 
HCP( )nmolicells106
HCP Total 
( )nmolicells106
Lipids 
( )nmolicells106
N-linked mAb 
( )nmolimgmAb
UDP-GlcNAc 1.248 — 1.248 — 49.14
GDP-Man 3.172 — 3.172 0.366 121.2
UDP-Glc 1.057 — 1.057 0.503 40.39
UDP-Gal 0.504 1.160 1.665 0.623 7.119
GDP-Fuc 0.140 — 0.140 — 12.23
CMP-Neu5Ac 0.034 1.409 1.443 0.403 0.155
CMP-Neu5Gc 0.007 — 0.007 — —
UDP-GalNAc — 1.160 1.160 0.092 —
Table 2.  HCP glycan frequency and NS stoichiometric coefficients for CHO cell and mAb glycosylation.
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of the enzymes involved in glycosylation are themselves glycoproteins54,55. Again, if activity of these enzymes 
relies on their carbohydrate composition, reduced NS availability could directly influence recombinant protein 
glycosylation while simultaneously decreasing glyco-enzyme activity, thus impacting overall protein glycosyla-
tion in a feed-forward manner. Although yet to be confirmed, these mechanisms could cause cascading effects 
whereby reduced NS availability may negatively impact protein folding as well as HCP and recombinant product 
glycosylation.
The remaining highly-abundant glycoproteins are cell adhesion and extracellular matrix components (chon-
droitin sulfate proteoglycan 4, laminin, fibronectin, annexin), cell surface receptors (CD44 antigen, integrin β ), 
the C-C motif chemokine 2, the Lysosome-associated membrane glycoprotein 1, and the amyloid beta A4 protein. 
Given the role of carbohydrates in cell-cell interactions56, the high observed abundance of cell surface, extracellu-
lar matrix, and secreted glycoproteins is expected.
Frequency of GAG, GPI, and O-Man glycosylation sites. GAG glycosites. Eleven proteoglycans were 
found in the CHO proteome, including syndecan, glypican, agrin, decorin, and lumican (ST10). These proteo-
glycans are reported to contain heparan, chondroitin, and keratin sulphate GAGs44. The total weighted frequency 
of proteoglycans across the CHO proteome was found to be 0.38 sites per 100 CHO HCPs (ST10). This value is 
over twenty-fold lower than the one obtained for N-linked glycosites and 70-fold lower than that of O-GalNAc 
glycosites. These results suggest that, although present, proteoglycans are in low abundance compared to N-linked 
and O-GalNAc glycoproteins, and do not contribute considerably to NS consumption towards CHO cellular gly-
cosylation, an observation that has also been made experimentally39. We therefore believe that our assumption of 
disregarding these HCP glycosylation types as considerable sinks for NS consumption is valid.
GPI glycosites. The PredGPI GPI-anchor prediction server (http://gpcr.biocomp.unibo.it/predgpi/) identified 
48 GPI-anchoring sites across the CHO proteome (ST10). The predicted GPI-anchoring sites were found on 
cell surface proteins (e.g. legumain, ephrin, the renin receptor, tissue plasminogen activator), secretory pathway 
proteins (e.g. ER-Golgi 24 kDa SNARE, transmembrane protein 115, Syntaxin-16), as well as various enzymes 
and chaperones (e.g. UMP-CMP kinase, lipoprotein lipase, tissue α -L-fucosidase, proteome assembly chap-
erone 2, peptidyl-prolyl cis-trans isomerase FKBP8). The weighted frequency of free and occupied GPI sites 
in CHO was found to be 0.447sites/100HCP and 1.655sites/100HCP, respectively. The total number of GPI 
sites (2.103sites/100HCP) is approximately four-fold lower than the frequency of HCP N-linked glycans and 
over 12-fold lower than HCP O-GalNAc glycosites. Given that the difference in glycosite frequency is rela-
tively low, the demand of NSs towards GPI glycosylation was included in our estimates. The monosaccharide 
composition of GPI glycans was assumed to be the one reported for the Hamster prion protein GPI-anchor 
(Man4Neu5AcGalNAcGlcN)57. The stoichiometric coefficients of NS consumption towards GPI synthesis were 
calculated using the obtained GPI frequency and the monosaccharide distribution for the Hamster prion protein 
GPI anchor, as described for the N-linked and O-GalNAc glycans in the materials and methods section. The sto-
ichiometric coefficients for lipid glycosylation presented in Table 2 are the sum of the stoichiometric coefficients 
for glycosphingolipid and GPI glycosylation. Individual values for GPI and glycosphingolipid stoichiometric 
coefficients are presented in Supplementary Table ST9.
Figure 4. Major N-linked and O-GalNAc glycoproteins in CHO. The ten proteins that contribute most 
to total N-linked (A) and O-GalNAc (B) glycosites are shown. The labels above the bars show the percent 
contribution of each individual glycoprotein to the total number of N-linked and O-GalNAc glycosylation sites. 
The name of each glycoprotein is shown on the right.
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O-Man glycosite frequency. Cadherins and plexins have been recently reported as the major O-mannosylated 
glycoproteins in humans58. This study reports 133 O-Man sites across 37 cadherins and 8 O-Man sites in 6 plex-
ins out of a total of 235 identified O-Man glycosites. A third major source of O-Man glycosites was reported to 
be α -dystroglycan, with 13 sites. In order to evaluate whether O-mannose glycans are considerable sinks for NS 
consumption in CHO cells, the database for closes homologs to the CHO proteome (ST1) was queried for the 
presence of cadherins, plexins, and α -dystroglycan. Three cadherins (protocadherin fat1, protocadherin fat 3, 
and cadherin 9), four plexins (A4, C1, D1, and A1), and α -dystroglycan were found across the CHO proteome. 
The total relative abundance of the above seven proteins plus α -dystroglycan was found to be 0.014% of the CHO 
proteome. In total, these eight proteins contain 11 confirmed O-Man sites58. When this value is multiplied by the 
total relative abundance of these proteins, this yields a weighted O-Man glycosite frequency of 0.154 sites per 100 
HCPs. This value is 50-fold lower than the number of N-linked glycosites and nearly 200-fold lower than that of 
O-GalNAc glycosites. This result confirms that O-Man glycans are in considerably lower abundance than other 
types of HCP glycosylation, and do not significantly contribute to NS consumption.
Stoichiometric coefficients for NSs consumed towards CHO cell glycosylation. The stoichio-
metric coefficients range over three orders of magnitude (Table 2) and are higher for monosaccharides that are 
abundant in the average glycoform structure (e.g. GlcNAc in N-linked glycosylation) and lower for less abun-
dant species (e.g. Neu5Gc). The high stoichiometric coefficients for GDP-Man and UDP-Glc towards N-linked 
glycosylation reflect the presence of their corresponding monosaccharides in the precursor oligosaccharide that 
initiates N-linked glycosylation, even though most of the mannose and all of the glucose residues are trimmed 
from the final structure through processing along the secretory pathway. It is worth noting that demand for these 
NSs may be lower considering that their monosaccharide components could be recycled after being cleaved off of 
the glycoprotein during the processing reactions.
Interestingly, the obtained stoichiometric coefficients for uridine diphosphate N-acetylglucosamine 
(UDP-GlcNAc) and uridine diphosphate N-acetylgalactosamine (UDP-GalNAc) towards HCP glycosylation 
are quite similar (1.248 nmol/106cells and 1.160 nmol/106cells, respectively) despite the notable difference in fre-
quency of each glycosylation type. The difference in N-linked and O-GalNAc glycosite frequencies is offset by 
the high average GlcNAc content of HCP N-linked glycans (3.54 nmolGlcNAcl/nmolN−glycan) compared with that for 
O-GalNAc HCP glycosylation (1.0 nmolGlcNAcl/nmolO−glycan).
Only two NSs, uridine diphosphate galactose (UDP-Gal) and cytosine monophosphate N-acetylneuraminic 
acid (CMP-Neu5Ac), are consumed for all considered forms of glycosylation (N-linked and O-GalNAc HCP, lipid 
glycosylation, and mAb N-linked glycosylation). The highest obtained stoichiometric coefficient for UDP-Gal 
consumption corresponds to O-GalNAc HCP glycosylation (ν = . nmol cells1 16 /10UDPGal
OglycHCP 6 ) and is due to the 
high frequency of identified O-GalNAc glycosylation sites across the CHO proteome21 (Table 2) and the presence 
of galactose in all O-GalNAc glycans20 (Fig. 2). The stoichiometric coefficient of UDP-Gal towards lipid glycosyl-
ation was calculated as ν = .− nmol cells0 623 /10UDP Gal
GL 6 , and surpasses that for HCP N-linked glycosylation 
(ν = . nmol cells0 504 /10UDPGal
NglycHCP 6 ). The higher stoichiometric coefficient for lipid glycosylation is likely due to the 
presence of galactose in the most abundant glycosphingolipids reported for CHO cells22,59.
Similarly to UDP-Gal, the highest obtained stoichiometric coefficient for CMP-Neu5Ac consumption is 
towards O-GalNAc HCP glycosylation (ν = . nmol cells1 443 /10UDPGal
OglycHCP 6 ). Again, this is due to the high frequency 
of O-GalNAc glycans across the CHO proteome and the high Neu5Ac content (at least one residue per glycan) of 
O-GalNAc glycans (Fig. 2). The second largest coefficient for CMP-Neu5Ac consumption is towards lipid glyco-
sylation (ν = . nmol cells0 403 /10CMPNeu Ac
GL
5
6 ), and is due to the presence of Neu5Ac on the GM3 ganglioside, which 
is the most abundant glycosphingolipid in CHO cells22,59. The low stoichiometric demand of CMP-Neu5Ac 
towards HCP N-linked glycosylation (ν = . nmol cells0 034 /10CMPNeu Ac
NglycHCP
5
6 ) is due to the low abundance of the cor-
responding monosaccharide in CHO HCP N-linked glycans (Fig. 2).
Partition of NS fluxes towards host cell and rTP glycosylation. Total NS fluxes. Total NS fluxes 
towards cellular and mAb glycosylation were estimated as described in the materials and methods section and 
Supplementary Table ST11. The highest demand of NSs towards cellular glycosylation can be observed at µRq
Low
/p g
, 
whereas the highest demand for product glycosylation will be observed at µRq
High
/p g
, thus bounding a range of meta-
bolic demand for cellular versus product glycosylation. The values for qp and μg extracted from these publications 
were multiplied by the corresponding stoichiometric coefficients presented in Table 2 to obtain the percentage of 
NS fluxes directed towards cellular N-linked, O-GalNAc, and lipid glycosylation, as well as product N-linked 
glycosylation (Fig. 5). For analysis, the fluxes of UDP-GlcNAc and UDP-GalNAc towards cellular glycosylation 
have been summed (UDP-HexNAc), given that they share a common biosynthetic pathway where UDP-GalNAc 
is produced from the epimerization reaction of UDP-GlcNAc16.
Figure 5 shows that the flux of UDP-Gal and CMP-sialic acid towards glycosylation is highest at µRq
Low
/p g
. This 
trend is possibly due to the higher total protein productivity (HCP and mAb) observed under this regime 
(Table 1), which ranges from .6 93
pg
cell h
prot  to .7 62
pg
cell h
prot  at µRq
Low
/p g
, and is reduced to between .3 20
pg
cell h
prot  to .6 11
pg
cell h
prot  for 
µRq
High
/p g
. In contrast, more guanosine diphosphate fucose (GDP-Fuc) is consumed for µRq
High
/p g
 in the Chus and Kant 
datasets, while UDP-HexNAc is also consumed more for µRq
High
/p g
 in the Kant dataset (Fig. 5). Specifically, the flux of 
GDP-Fuc towards glycosylation ( )pmol
cells h106
 goes from 24.5 (Chus-L) to 28.1 (Chus-H) and from 27.2 (Kant-L) to 
49.4 (Kant-H) (Fig. 5C–F). Similarly, the UDP-HexNAc flux increases from 157.2 (Kant-L) to 219.8 (Kant-H). For 
GDP-Fuc, this trend is likely due to the high percentage of protein productivity destined for mAb synthesis in the 
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Chus-H and Kant-H datasets (48.8% and 64.1%, respectively), along with the considerably lower fucose content 
of HCP glycans 

 .


0 40
mol
mol
Fuc
HCP glycan
 compared to that of mAb glycans 

 .


0 91
mol
mol
Fuc
mAb glycan
. Similar effects cause the 
observed increase in UDP-HexNAc flux towards glycosylation in the Kant-H scenario, although it may mainly 
occur due to the high qp, given that the HexNAc content 






mol
mol
HexNAc
glycan
 of HCP and mAb glycans is relatively similar 
(4.54 and 3.65, respectively).
Flux distributions towards cellular and mAb glycosylation. GDP-Fuc and UDP-HexNAc flux towards 
HCP and mAb glycosylation. GDP-Fuc is exclusively consumed for N-linked glycosylation and its flux is dis-
tributed between host cell proteins and recombinant mAb according to demand. In each of the cases tested, the 
majority of GDP-Fuc flux goes towards mAb production (between 73% and 97%) due to the low abundance of 
fucosylated species in HCP glycans (Fig. 2). The flux of UDP-HexNAc is more evenly distributed between HCP 
and mAb glycosylation. Except for the Dool-L dataset, more than half of the UDP-HexNAc flux goes towards 
mAb glycosylation (Fig. 5), which is likely due to the high GlcNAc content of mAb N-glycans (Fig. 2). Despite 
the typically higher demand towards mAb glycosylation, the flux of UDP-HexNAc towards HCP glycosylation 
is significant and ranges between 11.9% and 59.8%. UDP-HexNAc consumption towards HCP glycosylation is 
almost evenly split between N-linked and O-GalNAc glycosylation. This arises from the similar stoichiometric 
coefficients obtained for UDP-GlcNAc towards HCP N-linked glycosylation and UDP-GalNAc towards HCP 
mucin-type glycosylation.
UDP-Gal and CMP-Neu5Ac flux towards cellular and mAb glycosylation. For all scenarios, HCP mucin-type 
glycosylation consumes the majority of CMP-Neu5Ac (between 73.8% and 75.8%), and the second highest 
demand for this NS is observed for lipid glycosylation (21.1% to 21.7%). Interestingly, the distribution of 
CMP-Neu5Ac consumption is almost independent of µRq /p g, which is due to the scarcity of sialic acids in the mAb. 
Figure 5. Distribution of nucleotide sugar fluxes towards cellular and mAb glycosylation. Theoretical 
distributions of NS fluxes towards N-linked HCP, O-GalNAc HCP, glycosphingolipids, and mAb N-linked 
glycosylation at low (A,C,E) and high (B,D,F) µRq /p g values. The distributions were estimated by multiplying the 
stoichiometric coefficient for each NS (Table 2), by values of qp and μg reported for industrial cell lines 
(Table 1)24–26. The different datasets that are presented are Dool-L (A), Dool-H (B), Chus-L (C), Chus-H (D), 
Kant-L (E) and Kant-H (F). The percentage of total NS flux (axis) towards N-linked HCP (dark blue), 
O-GalNAc HCP (intermediate blue), lipid (light blue), and N-linked mAb (belted pattern) glycosylation is 
presented within the figure.
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For this reason, CMP-Neu5Ac consumption depends almost exclusively on the specific growth rate of CHO cells, 
and thus the distribution of its consumption remains nearly constant across different µRq /p g values.
The fraction of UDP-Gal flux consumed towards mucin-type glycosylation varies between 23.9% and 46.2% 
and is higher under conditions where µRq /p g is low (and thus, antibody synthesis rate and utilisation of UDP-Gal 
for mAb glycosylation is low). Under µRq
Low
/p g
, the UDP-Gal flux towards glycolipid synthesis is the next highest 
(21.9% to 24.8%), followed closely by HCP N-linked glycosylation (17.7% to 20.1%). Due to the low mAb produc-
tivity to growth ratio, only between 8.8% and 19.6% of the consumed UDP-Gal goes towards mAb N-linked gly-
cosylation. We must note that UDP-Gal consumption towards mAb glycosylation surpasses HCP N-linked 
glycosylation in the Kant-L dataset, a result that is due to the relatively high µRq
Low
/p g
 value observed for this engi-
neered cell line.
Under the µRq
High
/p g
 scenarios, consumption of UDP-Gal towards mAb glycosylation surpasses that of any other 
type of glycosylation, except for the Doolan-H dataset, where UDP-Gal consumption towards HCP O-GalNAc 
glycosylation is higher. Across all tested conditions for µRq /p g, between 47.2% and 91.2% of UDP-Gal is consumed 
towards HCP N-linked, O-GalNAc, and lipid glycosylation, the only exception being the Kant-H dataset where 
52.8% of all consumed UDP-Gal goes towards mAb glycosylation. In this context, we must highlight that the 
Kant-H data correspond to engineered CHO cells (overexpressing anti-apoptotic genes) being cultured under 
mild hypothermic conditions and in presence of sodium butyrate26. Under these conditions, the cells character-
ised by Kantardjieff et al. yield an exceptionally high specific mAb productivity (~100pg/cell/day), which causes 
the observed demand in UDP-Gal towards mAb glycosylation. Thus, it is possible to consider all other tested 
scenarios of µRq /p g  as more representative of typical CHO cell culture. In these typical CHO culture scenarios, 
more UDP-Gal is consumed towards cellular glycosylation than to product glycosylation, which is particularly 
relevant when considering NS precursor feeding strategies. Our results suggest that over half of NS precursors fed 
to control mAb galactosylation would be destined to cellular components and would not reach their intended 
target. This is consistent with previous findings where cell surface galactosylation was observed to increase more 
(up to four-fold) than mAb galactose content (up to two-fold) with different uridine-manganese-galactose feed-
ing strategies12.
The changes in UDP-Gal flux distributions observed at varying µRq /p g are the broadest observed in this study 
and are most likely due to the fact that this NS is the only one that is consumed for all considered forms of glyco-
sylation (HCP N-linked and O-GalNAc, lipid, and mAb glycosylation). Given the observed variability of 
UDP-Gal flux distributions, it is no surprise that cell surface galactose content has been reported to correlate well 
with antibody galactosylation12. Furthermore, these results indicate that the partition of UDP-Gal between cellu-
lar and product glycosylation may be one of the underlying causes of galactosylation-associated microheteroge-
neity of mAbs produced in CHO: if a substantial proportion of available UDP-Gal is continuously consumed for 
cellular glycosylation, availability of this NS may fluctuate considerably throughout cell culture, and thus, lead to 
variations in rTP galactose content.
When considering that excess uridine and galactose supplementation have been reported to hinder cell 
growth and final product titre10,12,13, our results for UDP-Gal flux distributions further highlight the importance 
of having accurate estimates for NS consumption towards HCP glycosylation. Indicative estimates for the con-
sumption of UDP-Gal towards HCP glycosylation are necessary to determine optimal uridine and galactose 
feeding strategies that ensure adequate rTP galactosylation while minimising (or completely avoiding) deleterious 
effects on cell growth and product yield.
The results obtained with our proposed framework are in qualitative agreement with previous findings, but the 
estimates could be influenced by: i) variations in the relative abundance of CHO HCPs and lipids, ii) variations in 
the occupancy of N-linked, O-GalNAc, and lipid glycosylation sites, and iii) changes in glycosylation microhet-
erogeneity. All three of the above are likely to vary over time, depending on cell culture conditions, NS precursor 
supplementation strategy, growth phase, and cellular metabolic state. Indeed (and possibly due to a combination 
of proteomic, macroheterogeneity, and microheterogeneity effects), qualitative variations in CHO cell surface 
glycosylation have been reported12,60. The overall framework presented herein could be readily applied, via the 
CHO cellular glycosylation calculator provided in the supplementary file, to any experimental data so that vari-
ations in the demand for NSs towards cellular and rTGP glycosylation can be represented for different cell lines 
grown under different culture conditions. Experimentally, these limitations can also be addressed by monitoring 
the relative abundance and glycosylation of the subset of CHO proteins that were found to contribute most to 
HCP glycosylation.
Conclusions
The work presented herein describes a strategy to estimate the metabolic demand of NSs towards protein and 
lipid glycosylation in CHO cells. The estimate combines the relative abundance of individual CHO host proteins 
with the number of N-linked and O-GalNAc glycosylation sites present on each HCP and the reported CHO HCP 
glycome. The stoichiometric demand of NSs towards glycolipid (glycosphingolipid and GPI anchor) synthesis 
has also been included. Overall, our results show that the consumption of NSs towards HCP glycosylation is, 
in most cases, significant and cannot be neglected when rationally designing NS precursor feeding strategies or 
while developing mechanistic mathematical models for cell growth and recombinant protein glycosylation. The 
obtained stoichiometric coefficients for NS consumption towards cellular glycosylation are a first approximation 
towards a fuller quantitative understanding of how the process of HCP, glycosphingolipid, and rTP glycosyla-
tion are integrated. In addition, we have identified a subset of CHO HCPs which, if monitored for abundance, 
glyco-site occupancy, and glycan microheterogeneity, could refine the obtained stoichiometric coefficients, and 
www.nature.com/scientificreports/
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thus improve our quantitative understanding of cellular and rTP glycosylation. In the future, analysis of the over-
all burden of protein glycosylation on cellular metabolism will lead to mechanistically-defined feeding strategies 
for quantitative and optimal control of rTP glycosylation.
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